Our Mission is "To contribute broadly to society through value
creation based on innovative research and development
activities for the betterment of healthcare and fuller lives
of people worldwide."
By channeling efforts into the research and development of new
drugs, Sumitomo Pharma aims to realize this Mission and
provide innovative and useful pharmaceuticals and healthcare
solutions to people in Japan and around the world.
We are committed to contributing to the betterment of healthcare and fuller lives of people in three disease areas - Oncology, Psychiatry & Neurology (CNS), and Other areas (urological diseases, gynecological diseases, rare diseases, infectious diseases, etc.) - as well as in such modalities as small molecules and regenerative medicine/cell therapy.
SCROLL
2005
Established Sumitomo Dainippon Pharma (now Sumitomo Pharma) through a merger between Dainippon Pharmaceutical and Sumitomo Pharmaceuticals.
Dainippon Pharmaceutical Co., Ltd.
“A long‑standing company established in the 19th century by pharmaceutical industry leaders with the aspiration of making good quality pharmaceuticals widely available”
Osaka Pharmaceuticals Co., Ltd. was established by 21
prominent leaders in the pharmaceutical industry in
Doshomachi, Osaka in 1897. In the following year of 1898,
the Pharmaceutical Plant was established in Ebie, Osaka. The
company acquired the semi‑governmental Dainippon
Pharmaceutical Company in Tokyo, and changed the name of the
company to Dainippon Pharmaceutical Co., Ltd.
Dainippon Pharmaceutical Co., Ltd. operated a
wide‑ranging business that included the manufacture and sale
of animal health products, food additives, and industrial
materials in addition to pharmaceuticals.
Sumitomo Pharmaceuticals Co., Ltd.
“A pharmaceutical company that grew out of a chemical manufacturer and inherited the business spirit and technology of Sumitomo“
Sumitomo Pharmaceuticals Co., Ltd. was established in 1984 from the Research, Development and Manufacturing divisions of Sumitomo Chemical Co., Ltd.’s pharmaceuticals business, as well as the Pharmaceutical Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company’s pharmaceuticals. Sumitomo Pharmaceuticals Co., Ltd. grew through the pharmaceuticals business with its focus on the cardiovascular/diabetes area, the CNS area, the immunology (inflammation/allergy) area, and the oncology/infection area.
2009
Acquired Sepracor Inc. (currently, Sumitomo Pharma America Inc.) in order to build in‑house development and marketing systems of the atypical antipsychotic developed in‑house in the U.S.
2012
Acquired Boston Biomedical, Inc. (currently, Sumitomo Pharma America Inc.), a US biotech company specializing in oncology area. Gained superb capability to discover and develop drugs in the area of oncology.
2013
Decided to enter the field of Regenerative Medicine/Cell Therapy, by leveraging the experience, know‑how, and network of contacts built through research in the field conducted over more than 20 years; established the Regenerative & Cellular Medicine Office as a dedicated business unit.
2014
Established research bases in the Kobe Biomedical Innovation Cluster in Hyogo Prefecture, aiming to create new innovations in regenerative medicine and cell therapy using iPS cells and other advanced technologies, by promoting research activities that leverage an environment where cutting‑edge information on regenerative medicine and cell therapy can be accessed.
2018
Completed “SMaRT,” a manufacturing plant for regenerative medicine & cell therapy - the world’s first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells, which makes the manufacture of investigational agents as well as early‑stage commercial production possible -within our Central Research Laboratories.
2019
Concluded the Agreement for Strategic Alliance with Roivant Sciences Ltd., thereby acquiring numerous pipeline assets, including those that have the potential to become blockbusters in the future, as well as DrugOME and Digital Innovation, the healthcare technology platforms which will accelerate our digital transformation (DX), and certain key employees. We accelerated our DX and pressed ahead with our “transformation into a data‑driven pharmaceutical company” as well as “creation of new value and operational reform,” with a view to attaining sustained growth.
2020
Established S‑RACMO Co., Ltd., a joint venture with Sumitomo Chemical, to develop manufacturing methods and manufacture products for the field of regenerative medicine/cell therapy and to undertake business as a Contract Development and Manufacturing Organization (CDMO) .
2022
Changed the trade name from “Sumitomo Dainippon Pharma” to “Sumitomo Pharma” and refreshed the Group’s identity under the globally recognized “Sumitomo” brand, to achieve continuous growth and advance to a new stage, amid the globalization of business, entry into new research areas such as oncology, and numerous challenges including large‑scale acquisitions and partnerships.
2024
Established RACTHERA Co., Ltd., a joint venture with Sumitomo
Chemical, to accelerate the commercialization of regenerative
medicine/cell therapy within the Sumitomo Chemical Group. With
personnel primarily seconded from Sumitomo Pharma, RACTHERA,
together with Sumitomo Chemical,
Sumitomo Pharma, and
S‑RACMO, is working as one to advance research and
development in regenerative medicine/cell therapy, aiming to
deliver new treatment options to patients as quickly as
possible.
We are committed to addressing areas of high unmet medical
needs, focusing on oncology, CNS, and other therapeutic areas,
and pursuing innovative drug discovery through modalities such
as small molecules and regenerative medicine/cell therapy.
In the U.S., we are working to maximize the value of our three
key products that form the foundation of our revenue base -
treatments for advanced prostate cancer, overactive bladder, and
uterine fibroids/endometriosis—as well as allogeneic processed
thymus tissue for pediatric congenital athymia.
In Japan, we are striving to maximize product value in our
strength areas - CNS, diabetes, and rare diseases - by
leveraging our strong commercial platform and relationships.
01
Through our ongoing R&D effort in the oncology area, we have built robust pipelines. Leveraging the insights gained, we continue to prioritize R&D in this area, where unmet medical needs remain substantial. In drug discovery, we aim to develop innovative products and healthcare solutions by enhancing our competitiveness through modality development utilizing proprietary technologies, alongside collaborative initiatives with academic institutions.
At the development stage, we seek to enhance the likelihood of success by conducting careful evaluations of data from short‑term, small‑scale clinical studies. These assessments help us identify the most suitable cancer types and clarify product value for multiple pipeline candidates currently undergoing early‑stage clinical evaluation.
02
In the CNS area, we are committed to continuous value creation by focusing on neurological disorders with high unmet medical needs, including neurodegenerative and rare diseases. In particular, we aim to develop innovative new drugs—such as disease‑modifying treatments—by applying our proprietary small molecule drug discovery technologies with strong CNS penetration to targets closely linked to clinical pathology.
We are also leveraging non‑clinical models with high relevance, such as iPS cells, while further enhancing our accumulated translational technologies, including EEG and imaging, to improve the probability of R&D success.
03
We have been engaged in research activities in regenerative medicine/cell therapy since the 1990s, drawing on foundational knowledge and intellectual property obtained through Sumitomo Chemical’s basic research using human ES cells, as well as Sumitomo Chemical’s joint research with RIKEN in the ophthalmology area.
In FY2024, to accelerate business development in this area, Sumitomo Chemical and Sumitomo Pharma established a joint venture company, RACTHERA. Together, we are promoting efforts to rapidly commercialize iPS cell‑derived products.
04
Sumitomo Pharma holds a diverse portfolio of assets, primarily in areas where we have already established a strong presence, including women’s health, urology, diabetes, rare diseases, and infectious diseases. In Japan, we place particular emphasis on diabetes, offering a variety of therapeutic drugs with different mechanisms of action to address diverse medical needs.
As part of our development pipeline, we are advancing research and development projects in collaboration with academia, including a universal influenza vaccine and malaria vaccines.
05
We recognize that human resources are a source of competitiveness and an important driver of innovation for pharmaceutical companies. Therefore, we have established a system that utilizes the abilities of individual employees and strives to develop human resources who can flexibly adapt to changes and take on new challenges.
Vigorously Implement “Value Creation Cycle”
to Establish a Unique Position Globally
Sumitomo Pharma will continue to amplify innovation and implement it in society by strongly accelerating “Value Creation Cycle,” which consists of “R&D,” “Sales/Expansion of indications,” “Profit acquisition,” and “Upgrading Technology and Strategies.” We define the position we aspire to establish as “Global Specialized Player (GSP),” which is achieved through strategic deepening and explosion via the above innovation process and through our contribution in a unique position in the global marketplace.
Sumitomo Pharma Group’s Philosophy
Mission
We share the significance of the Sumitomo Pharma Group's existence and commitment to society as our Mission throughout the Group.
The significance of our existence is to contribute to sustainable society in which people can be healthy and vibrant, through continuing to provide patients with innovative products and healthcare solutions and ensuring that these treatment options support not only patients but also their families and caregivers.
Our Mission is "To contribute broadly to society through value
creation based on innovative research and development activities
for the betterment of healthcare and fuller lives of people
worldwide."
By channeling efforts into the research and development of new
drugs, Sumitomo Pharma aims to realize this Mission and provide
innovative and useful pharmaceuticals and healthcare solutions to
people in Japan and around the world.
We are committed to contributing to the betterment of healthcare and fuller lives of people in three disease areas - Oncology, Psychiatry & Neurology (CNS), and Other areas (urological diseases, gynecological diseases, rare diseases, infectious diseases, etc.) - as well as in such modalities as small molecules and regenerative medicine/cell therapy.
Progress2005
2005
Established Sumitomo Dainippon Pharma (now Sumitomo Pharma) through a merger between Dainippon Pharmaceutical and Sumitomo Pharmaceuticals.
Dainippon Pharmaceutical Co., Ltd.
“A long‑standing company established in the 19th century by pharmaceutical industry leaders with the aspiration of making good quality pharmaceuticals widely available”
Osaka Pharmaceuticals Co., Ltd. was established by 21 prominent leaders in the pharmaceutical industry in Doshomachi, Osaka in 1897. In the following year of 1898, the Pharmaceutical Plant was established in Ebie, Osaka. The company acquired the semi‑governmental Dainippon Pharmaceutical Company in Tokyo, and changed the name of the company to Dainippon Pharmaceutical Co., Ltd. operated a wide ranging business that included the manufacture and sale of animal health products, food additives, and industrial materials in addition to pharmaceuticals.
Sumitomo Pharmaceuticals Co., Ltd.
“A pharmaceutical company that grew out of a chemical manufacturer and inherited the business spirit and technology of Sumitomo“
Sumitomo Pharmaceuticals Co., Ltd. was established in 1984 from the Research, Development and Manufacturing divisions of Sumitomo Chemical Co., Ltd.’s pharmaceuticals business, as well as the Pharmaceutical Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company’s pharmaceuticals. Sumitomo Pharmaceuticals Co., Ltd. grew through the pharmaceuticals business with its focus on the cardiovascular/diabetes area, the CNS area, the immunology (inflammation/allergy) area, and the oncology/infection area.
2009
Acquired Sepracor Inc. (currently, Sumitomo Pharma America Inc.) in order to build in‑house development and marketing systems of the atypical antipsychotic developed in‑house in the U.S.
2012
Acquired Boston Biomedical, Inc. (currently, Sumitomo Pharma America Inc.), a US biotech company specializing in oncology area. Gained superb capability to discover and develop drugs in the area of oncology.
2013
Decided to enter the field of Regenerative Medicine/Cell Therapy, by leveraging the experience, know‑how, and network of contacts built through research in the field conducted over more than 20 years; established the Regenerative & Cellular Medicine Office as a dedicated business unit.
2014
Established research bases in the Kobe Biomedical Innovation Cluster in Hyogo Prefecture, aiming to create new innovations in regenerative medicine and cell therapy using iPS cells and other advanced technologies, by promoting research activities that leverage an environment where cutting‑edge information on regenerative medicine and cell therapy can be accessed.
2018
Completed “SMaRT,” a manufacturing plant for regenerative medicine & cell therapy - the world’s first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells, which makes the manufacture of investigational agents as well as early‑stage commercial production possible -within our Central Research Laboratories.
2019
Concluded the Agreement for Strategic Alliance with Roivant Sciences Ltd., thereby acquiring numerous pipeline assets, including those that have the potential to become blockbusters in the future, as well as DrugOME and Digital Innovation, the healthcare technology platforms which will accelerate our digital transformation (DX), and certain key employees. We accelerated our DX and pressed ahead with our “transformation into a data‑driven pharmaceutical company” as well as “creation of new value and operational reform,” with a view to attaining sustained growth.
2020
Established S‑RACMO Co., Ltd., a joint venture with Sumitomo Chemical, to develop manufacturing methods and manufacture products for the field of regenerative medicine/cell therapy and to undertake business as a Contract Development and Manufacturing Organization (CDMO) .
2022
Changed the trade name from “Sumitomo Dainippon Pharma” to “Sumitomo Pharma” and refreshed the Group’s identity under the globally recognized “Sumitomo” brand, to achieve continuous growth and advance to a new stage, amid the globalization of business, entry into new research areas such as oncology, and numerous challenges including large‑scale acquisitions and partnerships.
2024
Established RACTHERA Co., Ltd., a joint venture with Sumitomo
Chemical, to accelerate the commercialization of regenerative
medicine/cell therapy within the Sumitomo Chemical Group. With
personnel primarily seconded from Sumitomo Pharma, RACTHERA,
together with
Sumitomo Chemical,
Sumitomo Pharma, and
S‑RACMO, is working as one to advance research and
development in regenerative medicine/cell therapy, aiming to
deliver new treatment options to patients as quickly as
possible.
We are committed to addressing areas of high unmet medical
needs, focusing on oncology, CNS, and other therapeutic areas,
and pursuing innovative drug discovery through modalities such
as small molecules and regenerative medicine/cell therapy.
In the U.S., we are working to maximize the value of our three
key products that form the foundation of our revenue base -
treatments for advanced prostate cancer, overactive bladder, and
uterine fibroids/endometriosis—as well as allogeneic processed
thymus tissue for pediatric congenital athymia.
In Japan, we are striving to maximize product value in our
strength areas - CNS, diabetes, and rare diseases - by
leveraging our strong commercial platform and relationships.
01
Through our ongoing R&D effort in the oncology area, we have built robust pipelines. Leveraging the insights gained, we continue to prioritize R&D in this area, where unmet medical needs remain substantial. In drug discovery, we aim to develop innovative products and healthcare solutions by enhancing our competitiveness through modality development utilizing proprietary technologies, alongside collaborative initiatives with academic institutions.
At the development stage, we seek to enhance the likelihood of success by conducting careful evaluations of data from short‑term, small‑scale clinical studies. These assessments help us identify the most suitable cancer types and clarify product value for multiple pipeline candidates currently undergoing early‑stage clinical evaluation.
02
In the CNS area, we are committed to continuous value creation by focusing on neurological disorders with high unmet medical needs, including neurodegenerative and rare diseases. In particular, we aim to develop innovative new drugs—such as disease‑modifying treatments—by applying our proprietary small molecule drug discovery technologies with strong CNS penetration to targets closely linked to clinical pathology.
We are also leveraging non‑clinical models with high relevance, such as iPS cells, while further enhancing our accumulated translational technologies, including EEG and imaging, to improve the probability of R&D success.
03
We have been engaged in research activities in regenerative medicine/cell therapy since the 1990s, drawing on foundational knowledge and intellectual property obtained through Sumitomo Chemical’s basic research using human ES cells, as well as Sumitomo Chemical’s joint research with RIKEN in the ophthalmology area.
In FY2024, to accelerate business development in this area, Sumitomo Chemical and Sumitomo Pharma established a joint venture company, RACTHERA. Together, we are promoting efforts to rapidly commercialize iPS cell‑derived products.
04
Sumitomo Pharma holds a diverse portfolio of assets, primarily in areas where we have already established a strong presence, including women’s health, urology, diabetes, rare diseases, and infectious diseases. In Japan, we place particular emphasis on diabetes, offering a variety of therapeutic drugs with different mechanisms of action to address diverse medical needs.
As part of our development pipeline, we are advancing research and development projects in collaboration with academia, including a universal influenza vaccine and malaria vaccines.
05
We recognize that human resources are a source of competitiveness and an important driver of innovation for pharmaceutical companies. Therefore, we have established a system that utilizes the abilities of individual employees and strives to develop human resources who can flexibly adapt to changes and take on new challenges.
Vigorously Implement “Value Creation Cycle” to Establish a Unique Position Globally
Sumitomo Pharma will continue to amplify innovation and implement it in society by strongly accelerating “Value Creation Cycle,” which consists of “R&D,” “Sales/Expansion of indications,” “Profit acquisition,” and “Upgrading Technology and Strategies.” We define the position we aspire to establish as “Global Specialized Player (GSP),” which is achieved through strategic deepening and explosion via the above innovation process and through our contribution in a unique position in the global marketplace.
Sumitomo Pharma Group’s Philosophy
Mission
We share the significance of the Sumitomo Pharma Group's existence and commitment to society as our Mission throughout the Group.
The significance of our existence is to contribute to sustainable society in which people can be healthy and vibrant, through continuing to provide patients with innovative products and healthcare solutions and ensuring that these treatment options support not only patients but also their families and caregivers.
